A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan.
Latest Information Update: 09 May 2022
At a glance
- Drugs Rotavirus W179-9 vaccine (Primary)
- Indications Rotavirus infections
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 25 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.